FTSE 100: Index falls as earnings results weigh; pound below $1.33, Bodycote soars
Jeffrey B. Mirviss, Executive Vice President and President of Peripheral Interventions at Boston Scientific Corp (NYSE:BSX), recently reported a significant stock transaction. According to an SEC filing, Mirviss sold 13,022 shares of the company’s common stock on February 12, 2025. These shares were sold at a weighted average price of $105.06, generating a total of approximately $1.37 million. This sale was executed under a pre-established Rule 10b5-1 trading plan. The transaction comes as Boston Scientific trades near its 52-week high of $107.17, with the stock showing remarkable strength, up 62.8% over the past year. According to InvestingPro analysis, the stock appears to be trading above its Fair Value.
Additionally, Mirviss acquired 23,760 shares on February 11, 2025, without any monetary transaction, as part of the company’s 2022 Total (EPA:TTEF) Shareholder Return Performance Share Program. This acquisition was based on the company’s performance relative to the S&P 500 Health Care Index over a three-year period. Following these transactions, Mirviss holds 28,454 shares of Boston Scientific stock.
In other recent news, Boston Scientific Corporation has been the subject of several analyst upgrades, following a strong financial performance. Stifel analysts raised their price target for the company from $115 to $120, maintaining a positive outlook based on the company’s potential for significant operating leverage opportunities. RBC Capital Markets also increased their target to $116, citing the company’s robust fourth-quarter performance and initial guidance for 2025 that surpassed consensus expectations. Truist Securities echoed these sentiments, lifting their target to $120 and highlighting the potential for future earnings beats and upward revisions. Mizuho (NYSE:MFG) Securities offered the highest target at $130, noting the company’s strong sales and promising product developments.
In related developments, Boston Scientific announced that board member Charles J. Dockendorff will not seek re-election at the upcoming 2025 Annual Meeting of Stockholders. The company has not yet indicated any potential candidates to fill the vacancy on the board. These are some of the recent developments that have been shaping the narrative around Boston Scientific Corporation.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.